Pillar · Immunology research
Immune and Antimicrobial Peptide Research
Antimicrobial peptides are an ancient arm of innate immunity found across essentially all multicellular life. Immunomodulatory peptides work differently, tuning adaptive immune responses rather than killing pathogens directly. This hub covers both, including why antimicrobial peptides attract so much attention in the context of antibiotic resistance and why translation has proved difficult.
Evidence position
Emerging human research
Research evidence, established clinical evidence and regulatory approval are three different things. This page distinguishes them throughout and does not present research compounds as approved treatments.
How antimicrobial peptides kill
Most are cationic and amphipathic: positive charge draws them to the negatively charged surface of bacterial membranes, and the hydrophobic face inserts into the lipid bilayer, forming pores or destabilising the membrane. Because the target is a physical membrane property rather than a specific protein, resistance is thought to develop more slowly than with conventional antibiotics — though it does occur.
Why translation has been hard
Systemic development of antimicrobial peptides has repeatedly stalled on proteolytic instability, salt sensitivity in physiological conditions, and dose-limiting toxicity to host cells at concentrations near the therapeutic range. Topical applications, where local concentration can be controlled, have progressed further than systemic ones.
Immunomodulation rather than killing
Thymic peptides act on T-cell maturation and dendritic-cell function. This class has the strongest regulatory record in the hub: at least one thymic peptide is an approved medicine in several jurisdictions for defined indications, which is a materially different evidence position to most compounds on this site.
Compounds studied in this area
| Compound | What it is | Evidence tier |
|---|---|---|
| Thymosin Alpha-1 | A thymic peptide studied in T-cell function; approved for defined indications in some jurisdictions. | Established clinical evidence |
| LL-37 | The only human cathelicidin; studied in antimicrobial and wound contexts. | Early laboratory research |
| KPV | An alpha-MSH fragment studied in inflammatory models of gut and skin. | Early laboratory research |
| Defensins | A broad family of innate-immune peptides, largely at laboratory stage as therapeutics. | Early laboratory research |
Key takeaways
- Antimicrobial peptides are an ancient arm of innate immunity found across essentially all multicellular life. Immunomodulatory peptides work differently, tuning adaptive immune responses rather than killing pathogens directly. This hub covers both, including why antimicrobial peptides attract so much attention in the context of antibiotic resistance and why translation has proved difficult.
- Overall evidence position for this topic: emerging human research.
- Findings in cells or animals are hypotheses about humans, never demonstrations in humans.
- Nothing on this page is medical advice, a protocol, or a dosing recommendation.
Frequently asked questions
Could antimicrobial peptides replace antibiotics?
Not currently. Instability, salt sensitivity and host-cell toxicity have limited systemic development; topical applications are further advanced.
Is Thymosin Alpha-1 approved anywhere?
Yes — it is approved for defined indications in several jurisdictions, which distinguishes it from most research peptides discussed on this site.
Continue reading
Related research hubs
Peptide Science
How peptides are built, how they signal, how they are synthesised and how they are studied — the foundational science behind every other topic on this site.
Regenerative Peptides
BPC-157, TB-500, GHK-Cu and related sequences studied in tendon, ligament, muscle and wound-healing models — mechanisms, evidence tiers and honest limitations.
Peptide Safety
What is actually known about peptide safety — immunogenicity, contamination, unknown long-term profiles, and why absence of reported harm is not evidence of safety.
About this page
Written and reviewed by the Peptide Intel Hub Editorial Team. Last reviewed 8 September 2026.
Scientific disclaimer: this page is educational and does not constitute medical advice. Research compounds referenced here are not approved treatments. See our research disclaimer.